- FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- Changes to the Roche Enlarged Corporate Executive Committee
- Wechsel in der erweiterten Konzernleitung von Roche
- Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
- FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
- Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
More ▼
Key statistics
As of last trade, Roche Holding AG (RHHBY:QXI) traded at 32.39, 10.92% above the 52 week low of 29.20 set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.04 |
---|---|
High | 32.41 |
Low | 32.04 |
Bid | -- |
Offer | -- |
Previous close | 32.01 |
Average volume | 2.75m |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 16.15 |
Market cap | 209.55bn USD |
EPS (TTM) | 1.98 USD |
Annual div (ADY) | 1.35 USD |
---|---|
Annual div yield (ADY) | 4.22% |
Div ex-date | Mar 14 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of Jun 03 2024 19:36 BST.
More ▼